Next Article in Journal
Current Evidence of Chinese Herbal Constituents with Effects on NMDA Receptor Blockade
Next Article in Special Issue
Nanoparticles as Drug Delivery Systems in Cancer Medicine: Emphasis on RNAi-Containing Nanoliposomes
Previous Article in Journal
The Inhibition of Stat5 by a Peptide Aptamer Ligand Specific for the DNA Binding Domain Prevents Target Gene Transactivation and the Growth of Breast and Prostate Tumor Cells
Open AccessReview

Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action

Hematology/Oncology Division, Penn State Hershey Medical Center, Hershey, PA 17033, USA
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2013, 6(8), 988-1038; https://doi.org/10.3390/ph6080988
Received: 4 June 2013 / Revised: 30 July 2013 / Accepted: 16 August 2013 / Published: 21 August 2013
(This article belongs to the Special Issue Chemotherapeutic Agents)
The use of pharmaceuticals for colon cancer treatment has been increasingly personalized, in part due to the development of new molecular tools. In this review, we discuss the old and new colon cancer chemotherapeutics, and the parameters that have been shown to be predictive of efficacy and safety of these chemotherapeutics. In addition, we discuss how alternate pharmaceuticals have been developed in light of a potential lack of response or resistance to a particular chemotherapeutic. View Full-Text
Keywords: colorectal cancer; personalized medicine; genetic polymorphisms colorectal cancer; personalized medicine; genetic polymorphisms
Show Figures

Figure 1

MDPI and ACS Style

Kline, C.L.B.; El-Deiry, W.S. Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action. Pharmaceuticals 2013, 6, 988-1038.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop